Loading...
XSTO
BIOWKS
Market cap15mUSD
May 28, Last price  
1.85SEK
1D
-0.54%
1Q
26.71%
IPO
-81.73%
Name

Bio-Works Technologies AB

Chart & Performance

D1W1MN
P/E
—
P/S
5.72
EPS
—
Div Yield, %
—
Shrs. gr., 5y
20.95%
Rev. gr., 5y
35.51%
Revenues
25m
-41.99%
1,542,0003,677,0004,945,0006,563,0005,573,0007,234,00021,910,00041,320,00043,896,00025,465,000
Net income
-37m
L-34.25%
-12,361,000-17,157,000-23,657,000-37,955,000-42,113,000-44,549,000-12,942,000-44,950,000-56,821,000-37,357,000
CFO
-43m
L-26.82%
-13,123,000-14,457,000-21,232,000-34,689,000-40,041,000-43,359,000-13,369,000-39,880,000-58,990,000-43,168,000

Profile

Bio-Works Technologies AB (publ), a biotechnology company, researches, develops, manufactures, and supplies agarose-based separation products to purify proteins, peptides, and other biomolecules primarily in Sweden. It offers activated and affinity resins; BabyBio columns; immobilized metal-ion affinity chromatography resins; ion exchange resins; OptioBio glass columns; screening kits; and size exclusion chromatography resins. The company's products are used in antibodies, his-tagged proteins, proteins, peptides, oligonucleotides, and viruses and vaccines applications. Bio-Works Technologies AB (publ) founded in 2006 and is headquartered in Uppsala, Sweden.
URL
https://www.bio-works.com
IPO date
Dec 14, 2017
Employees
48
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
25,465
-41.99%
43,896
6.23%
41,320
88.59%
Cost of revenue
5,449
17,075
12,473
Unusual Expense (Income)
NOPBT
20,016
26,821
28,847
NOPBT Margin
78.60%
61.10%
69.81%
Operating Taxes
76
2,087
255
Tax Rate
0.38%
7.78%
0.88%
NOPAT
19,940
24,734
28,592
Net income
(37,357)
-34.25%
(56,821)
26.41%
(44,950)
247.32%
Dividends
Dividend yield
Proceeds from repurchase of equity
38,980
33,652
4,038
BB yield
-51.92%
-13.12%
-0.55%
Debt
Debt current
(10,373)
Long-term debt
Deferred revenue
Other long-term liabilities
2
6,797
Net debt
(34,279)
(39,382)
(76,248)
Cash flow
Cash from operating activities
(43,168)
(58,990)
(39,880)
CAPEX
(8)
(860)
(1,124)
Cash from investing activities
158
(860)
(1,124)
Cash from financing activities
37,753
33,263
4,038
FCF
14,529
22,272
29,992
Balance
Cash
34,279
39,382
65,875
Long term investments
Excess cash
33,006
37,187
63,809
Stockholders' equity
7,796
(301,860)
(245,322)
Invested Capital
36,790
345,893
302,641
ROIC
10.42%
7.63%
9.38%
ROCE
44.89%
60.91%
50.33%
EV
Common stock shares outstanding
77,960
36,113
35,006
Price
0.96
-86.44%
7.10
-66.19%
21.00
-23.64%
Market cap
75,075
-70.72%
256,404
-65.12%
735,120
-14.34%
EV
40,796
217,022
658,872
EBITDA
20,530
27,432
29,322
EV/EBITDA
1.99
7.91
22.47
Interest
9
3
23
Interest/NOPBT
0.04%
0.01%
0.08%